Head-to-head · WeighScore
Kova vs Omada Health
The verdict
Omada Health takes it — 55.6/100 to 44.3/100.
Omada Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Omada Health is a virtual care company offering behavior-change programs for weight health, diabetes and hypertension, distributed through employers and health plans.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kova | Omada Health |
|---|---|---|
| WeighScore | 44.3/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #498 | #436 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #498 · C
Strengths
- Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
- Medication is included in the plan price, with no separate pharmacy charge
- States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
- Companion app tracks weight, protein and side effects, with medication schedule reminders
- You are not charged unless a provider approves treatment
Where it loses points
- At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
- The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
- Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
- Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
- No pharmacy or prescribing medical group is named anywhere on the site
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.